IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v10y2019i1d10.1038_s41467-019-10043-0.html
   My bibliography  Save this article

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

Author

Listed:
  • Naiara Martínez-Vélez

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Marc Garcia-Moure

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Miguel Marigil

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Marisol González-Huarriz

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Montse Puigdelloses

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Jaime Gallego Pérez-Larraya

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Marta Zalacaín

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Lucía Marrodán

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Maider Varela-Guruceaga

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Virginia Laspidea

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Jose Javier Aristu

    (Health Research Institute of Navarra (IDISNA)
    Clínica Universidad de Navarra)

  • Luis Isaac Ramos

    (Health Research Institute of Navarra (IDISNA)
    Clínica Universidad de Navarra)

  • Sonia Tejada-Solís

    (Health Research Institute of Navarra (IDISNA)
    Clínica Universidad de Navarra)

  • Ricardo Díez-Valle

    (Health Research Institute of Navarra (IDISNA)
    Clínica Universidad de Navarra)

  • Chris Jones

    (The Institute of Cancer Research
    The Institute of Cancer Research)

  • Alan Mackay

    (The Institute of Cancer Research
    The Institute of Cancer Research)

  • Jose A. Martínez-Climent

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra, CIBERONC, Pamplona)

  • Maria Jose García-Barchino

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra, CIBERONC, Pamplona)

  • Eric Raabe

    (The Johns Hopkins University School of Medicine
    The Johns Hopkins University School of Medicine)

  • Michelle Monje

    (Stanford University School of Medicine)

  • Oren J. Becher

    (Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital)

  • Marie Pierre Junier

    (Sorbonne Universities)

  • Elias A. El-Habr

    (Sorbonne Universities)

  • Herve Chneiweiss

    (Sorbonne Universities)

  • Guillermo Aldave

    (Texas Children’s Hospital, Baylor College of Medicine)

  • Hong Jiang

    (The University of Texas MD Anderson Cancer Center)

  • Juan Fueyo

    (The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center)

  • Ana Patiño-García

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

  • Candelaria Gomez-Manzano

    (The University of Texas MD Anderson Cancer Center)

  • Marta M. Alonso

    (Health Research Institute of Navarra (IDISNA)
    University of Navarra
    Clínica Universidad de Navarra)

Abstract

Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic approach. Delta-24-RGD is a replication competent adenovirus engineered to replicate in tumor cells with an aberrant RB pathway. This virus has proven to be safe and effective in adult gliomas. Here we report that the administration of Delta-24-RGD is safe in mice and results in a significant increase in survival in immunodeficient and immunocompetent models of pHGG and DIPGs. Our results show that the Delta-24-RGD antiglioma effect is mediated by the oncolytic effect and the immune response elicited against the tumor. Altogether, our data highlight the potential of this virus as treatment for patients with these tumors. Of clinical significance, these data have led to the start of a phase I/II clinical trial at our institution for newly diagnosed DIPG (NCT03178032).

Suggested Citation

  • Naiara Martínez-Vélez & Marc Garcia-Moure & Miguel Marigil & Marisol González-Huarriz & Montse Puigdelloses & Jaime Gallego Pérez-Larraya & Marta Zalacaín & Lucía Marrodán & Maider Varela-Guruceaga & , 2019. "The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models," Nature Communications, Nature, vol. 10(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-10043-0
    DOI: 10.1038/s41467-019-10043-0
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-019-10043-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-019-10043-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-10043-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.